Issue 9/2019
Content (8 Articles)
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin, Constantine Alifrangis
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer, Susan Griffin
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
Marina Treskova, Stefan M. Scholz, Alexander Kuhlmann
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
Mario J. N. M. Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, Min Huang, Nicholas Latimer, Andrew Briggs
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample
Christine Mpundu-Kaambwa, Gang Chen, Elisabeth Huynh, Remo Russo, Julie Ratcliffe
Severity-Adjusted Probability of Being Cost Effective
Matthijs M. Versteegh, Isaac Corro Ramos, Nasuh C. Buyukkaramikli, Amir Ansaripour, Vivian T. Reckers-Droog, Werner B. F. Brouwer
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe
Dominik Golicki, Michał Jakubczyk, Katarzyna Graczyk, Maciej Niewada
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
Thomas E. Delea, Xinke Zhang, Jordan Amdahl, Diana Boyko, Franziska Dirnberger, Marco Campioni, Ze Cong